Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Medicines licensing

Cystic fibrosis therapy approved by US Food and Drug Administration

A combination therapy of two drugs that target the most common genetic mutation responsible for cystic fibrosis (CF) has been given a licence in the United States. In the image, a CT scan of a patient with cystic fibrosis (axial view)

Source: Scott Camazine / Alamy

US patients with the most common genetic mutation responsible for cystic fibrosis have a new treatment option after the approval of lumacaftor/ivacaftor

A combination therapy of two drugs that target the most common genetic mutation responsible for cystic fibrosis (CF) has been given a licence in the United States.

Lumacaftor 200mg/ivacaftor 125mg (Orkambi) was given breakthrough designation status by the US Food and Drug Administration (FDA), which means its approval was fast-tracked in recognition of the substantial impact it could have for patients.

The approval significantly broadens the treatment options for CF patients with specific genetic defects, says the FDA.

The product — which has orphan drug status in both Europe and the United States because CF is a rare condition — is designed for patients who have the F508del mutation. The mutation causes a processing defect that drastically reduces levels of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, an anion channel that manages the movement of salt and water into and out of cells. Having two copies of this mutation — one inherited from each parent — is the leading cause of CF and accounts for almost half of all patients with the disease.

The decision to approve the drug combination for patients aged 12 and older follows the results of two double-blind and placebo-controlled clinical trials of 1,108 patients who had the specific mutation. Lung function was improved in patients who took the drug compared with those who were given placebo.

The drug is manufactured by Vertex Pharmaceuticals, which describes its approval as a “fundamental change” in the treatment of CF. The company promised that Orkambi would be available in the United States within days of the FDA announcement on 2 July 2015.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068917

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • A combination therapy of two drugs that target the most common genetic mutation responsible for cystic fibrosis (CF) has been given a licence in the United States. In the image, a CT scan of a patient with cystic fibrosis (axial view)

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.